loading
Precedente Chiudi:
$6.99
Aprire:
$6.98
Volume 24 ore:
147.03K
Relative Volume:
0.17
Capitalizzazione di mercato:
$418.23M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-7.857
EPS:
-0.9062
Flusso di cassa netto:
-
1 W Prestazione:
-3.91%
1M Prestazione:
-26.67%
6M Prestazione:
+300.00%
1 anno Prestazione:
+217.86%
Intervallo 1D:
Value
$6.92
$7.55
Intervallo di 1 settimana:
Value
$6.56
$7.80
Portata 52W:
Value
$0.8786
$12.09

Adlai Nortye Ltd Adr Stock (ANL) Company Profile

Name
Nome
Adlai Nortye Ltd Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
123
Name
Cinguettio
Name
Prossima data di guadagno
2025-12-03
Name
Ultimi documenti SEC
Name
ANL's Discussions on Twitter

Compare ANL vs VRTX, REGN, ALNY, ARGX, INSM

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ANL icon
ANL
Adlai Nortye Ltd Adr
7.12 418.23M 0 0 0 -0.9062
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 31.97B 606.42M -1.28B -997.58M -6.403

Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-20 Iniziato Leerink Partners Outperform
2026-02-13 Aggiornamento H.C. Wainwright Neutral → Buy
2025-06-02 Downgrade H.C. Wainwright Buy → Neutral
2024-09-04 Iniziato H.C. Wainwright Buy
2023-10-24 Iniziato Cantor Fitzgerald Overweight

Adlai Nortye Ltd Adr Borsa (ANL) Ultime notizie

pulisher
Mar 22, 2026

Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's why - MSN

Mar 22, 2026
pulisher
Mar 19, 2026

Adlai Nortye Ltd. Sponsored ADR (ANL) Raised to Buy: The Reason Behind This Change - Bitget

Mar 19, 2026
pulisher
Mar 19, 2026

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance

Mar 19, 2026
pulisher
Mar 13, 2026

ETFs Investing in Adlai Nortye Ltd. Sponsored ADR Stocks - TradingView

Mar 13, 2026
pulisher
Mar 10, 2026

Adlai Nortye (NASDAQ: ANL) files $600M shelf; 21.5M ADSs resale - Stock Titan

Mar 10, 2026
pulisher
Mar 09, 2026

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Mar 09, 2026
pulisher
Mar 06, 2026

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX) - The Globe and Mail

Mar 06, 2026
pulisher
Mar 05, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Mar 05, 2026
pulisher
Feb 27, 2026

Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail

Feb 27, 2026
pulisher
Feb 25, 2026

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail

Feb 25, 2026
pulisher
Feb 24, 2026

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail

Feb 24, 2026
pulisher
Feb 19, 2026

Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Feb 19, 2026
pulisher
Feb 13, 2026

Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic - TipRanks

Feb 13, 2026
pulisher
Feb 13, 2026

H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target - Investing.com South Africa

Feb 13, 2026
pulisher
Feb 12, 2026

Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks

Feb 12, 2026
pulisher
Feb 12, 2026

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.

Feb 12, 2026
pulisher
Feb 11, 2026

Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat

Feb 11, 2026
pulisher
Feb 04, 2026

Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - The Globe and Mail

Feb 04, 2026
pulisher
Feb 03, 2026

Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa

Feb 03, 2026
pulisher
Feb 03, 2026

Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks

Feb 03, 2026
pulisher
Feb 03, 2026

Adlai Nortye raises $140 million in private placement - Investing.com

Feb 03, 2026
pulisher
Jan 30, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World

Jan 30, 2026
pulisher
Jan 30, 2026

AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World

Jan 30, 2026
pulisher
Jan 29, 2026

United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com - Investing.com India

Jan 29, 2026
pulisher
Jan 29, 2026

United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com India

Jan 29, 2026
pulisher
Jan 29, 2026

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com

Jan 29, 2026
pulisher
Jan 29, 2026

Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating - Investing.com India

Jan 29, 2026
pulisher
Jan 29, 2026

Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating By Investing.com - Investing.com South Africa

Jan 29, 2026
pulisher
Jan 29, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat

Jan 29, 2026
pulisher
Jan 28, 2026

Analysts’ Top Healthcare Picks: Kura Oncology (KURA), UnitedHealth (UNH) - The Globe and Mail

Jan 28, 2026
pulisher
Jan 22, 2026

Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail

Jan 22, 2026
pulisher
Jan 14, 2026

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail

Jan 14, 2026
pulisher
Jan 13, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World

Jan 13, 2026
pulisher
Jan 13, 2026

Short Interest in Global X Social Media ETF (NASDAQ:SOCL) Increases By 7,184.3% - Defense World

Jan 13, 2026
pulisher
Jan 13, 2026

TerraVest Industries (TSE:TVK) Price Target Raised to C$209.00 at Canaccord Genuity Group - Defense World

Jan 13, 2026
pulisher
Jan 13, 2026

Paycom Software (NYSE:PAYC) Price Target Cut to $185.00 by Analysts at Barclays - Defense World

Jan 13, 2026
pulisher
Jan 13, 2026

Teledyne Technologies (NYSE:TDY) Given New $579.00 Price Target at Barclays - Defense World

Jan 13, 2026
pulisher
Jan 12, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat

Jan 12, 2026
pulisher
Jan 03, 2026

Adlai Nortye narrows first-half 2025 loss as oncology pipeline advances - MSN

Jan 03, 2026
pulisher
Jan 02, 2026

Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Sahm

Jan 02, 2026
pulisher
Dec 31, 2025

Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - MSN

Dec 31, 2025
pulisher
Dec 30, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xoma (XOMA) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail

Dec 30, 2025
pulisher
Dec 30, 2025

Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm

Dec 30, 2025
pulisher
Dec 29, 2025

Adlai Nortye Ltd ADR (ANL-Q) Stock Price and News - The Globe and Mail

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal By Investing.com - Investing.com South Africa

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm By Investing.com - Investing.com South Africa

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm - Investing.com India

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye Narrows First-Half 2025 Loss as Oncology Pipeline Advances - TipRanks

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal - Investing.com

Dec 29, 2025
pulisher
Dec 29, 2025

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Sahm

Dec 29, 2025

Adlai Nortye Ltd Adr Azioni (ANL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
Capitalizzazione:     |  Volume (24 ore):